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While patients in the younger group were more likely to
be male (69.3%), the majority of patients in 15–18 age
category were female (59.3%). Older patients were less
likely to receive psychotherapy treatment (P  0.01).
During the year, 99 (21.5%) patients were hospitalized
for depression. Females were more likely to receive more
than one class of antidepressant (24.1% vs. 13.39%).
The difference was more pronounced within the 15–18
age category (26.3% vs. 11.0%). Hospitalization rates
were higher among older patients (25.2%) compared to
younger patients (11.8%). Hospitalization was not re-
lated to the presence of psychotherapy, but it was associ-
ated with the multiple antidepressant treatment (P 
0.01). CONCLUSION: Hospitalization was a common
outcome for patients, suggesting the need for improved
treatment.
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Drug-drug interactions are well documented and are
known to change pharmacokinetic properties of an
agent, affecting efficacy and increasing the risk for side
effects or adverse events. While clinical trial and labora-
tory data assess the mechanism of these interactions, a
compelling part of the picture is missing, the clinical and
economic consequences associated with these events. OB-
JECTIVES: The purpose of this analysis was to identify
changes in incurred charges related to the treatment of
depression with respect to the concurrent use of drugs
with interaction potential. METHODS: Complete medi-
cal and pharmacy claim records were collected for pa-
tients with depression by using an episoding methodol-
ogy. Data collection began with the episode start and
continued for 1 year. For patients with the use of specific
antidepressants, cohorts were formed using the presence
of concurrent use with other prescription drugs having
documented interaction potential. Total depression
related expenditures for patients with concurrent drug
use were collected and compared to a matched patient
group. RESULTS: A total of 4,655 patients were selected
for observation, 1,681 had evidence of at least one (1) in-
stance of co-administration of interacting agents. Of all
patients, fluoxetine users had the greatest percentage of
co-administration (39.9%) and bupropion users had
the least amount (7.9%). When observing incurred
healthcare charges, the average total yearly charges for
treating depression were 35% higher for patients with
the presence of drug co-administration than compared
to matched patient group ($2,513 vs. $1,860, respec-
tively, P  0.001). Service categories that were major
drivers included professional visits, testing, outpatient fa-
cility, and prescription drugs. CONCLUSIONS: The
presence of antidepressant drug co-administration seems
to correlate with increased charges specific to the treat-
ment of depression. This information is a compelling in-
dicator that drug interactions are clinically significant
and have serious economic consequences. Careful selec-
tion of antidepressants can avoid additional resource uti-
lization.
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With the introduction of atypical neuroleptic medications
into the market place, usage of conventional neuroleptics
has fallen with the perception of a more favorable atypi-
cal side effect profile. Although there is some evidence
that atypical neuroleptics are associated with a decreased
occurrence of tardive dyskinesia (TD), reports of atypi-
cal-induced TD are appearing in the literature. OBJEC-
TIVE: The purpose of this study was to determine the
risk of TD associated with atypical and conventional
neuroleptics. METHODS: Subjects were adult users of
the Veterans Administration Puget Sound Health Care
System who received 1 prescriptions for neuroleptic
medications during the study period. Electronic medical
and pharmacy records were used to obtain neuroleptic
drug exposure, exclusionary diagnosis, diagnosis for TD,
and select demographic data. Medical records were re-
viewed to collect demographic data not available elec-
tronically. The case-defining event was the diagnosis of
TD. Controls were randomly selected from a cohort of
neuroleptic users without TD. RESULTS: There were 48
cases and 179 controls for the final analysis. The only de-
mographic difference found was a higher proportion of
cases (92%) than controls (76%) were Caucasian. Con-
ventional neuroleptic users had an insignificant increase
in risk of TD over atypical neuroleptic users (OR  1.16;
95%CI  0.607–2.21). After adjusting for age, gender,
race, schizophrenia, schizo-affective disorder, depression,
and antiparkinson drugs, there was still no significant
difference in risk of TD between cases and controls (OR 
1.46; 95% CI  0.625–3.414). CONCLUSIONS: These
results suggest users of conventional neuroleptics may be
at increased risk of TD compared to users of atypical
neuroleptics, however in this population the increase was
not significant.
